# Helen Torley

Type: Person

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/helen-torley
Canonical HTML page: https://getbiobrief.com/entity/helen-torley

## Recent coverage (1 stories)

### Halozyme Q4 2025: ENHANZE Royalty Growth and Opdivo SC Launch Outlook
2026-02-19 04:14:32 · Sentiment: Neutral · Impact: 6/10 · Sources: 3

Halozyme Therapeutics reported robust Q4 2025 results, driven by record royalty revenue from its ENHANZE drug-delivery platform and key partnerships with Roche and Argenx. The company is positioning 2026 as a transformative year, centered on the high-stakes commercial launch of subcutaneous Opdivo in collaboration with Bristol Myers Squibb.
Full story: https://getbiobrief.com/story/halozyme-q4-2025-earnings-analysis-enhanze-royalty-growth

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.